Induction of antibody responses to African horse sickness virus (AHSV) in ponies after vaccination with recombinant modified vaccinia Ankara (MVA)

PLoS ONE

Volumn 4, Issue 6, 2009, Pages

  Chiam, Rachael ^a,f   Sharp, Emma ^a   Maan, Sushila ^b   Rao, Shujing ^b,e   Mertens, Peter ^b   Blacklaws, Barbara ^c   Davis Poynter, Nick ^d   Wood, James ^c   Castillo Olivares, Javier ^a,b  

^a ANIMAL HEALTH TRUST   (United Kingdom)

^b INSTITUTE FOR ANIMAL HEALTH   (United Kingdom)

^c Department of Veterinary Medicine ^*  (United Kingdom)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e CLEMSON UNIVERSITY   (United States)

^f WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; NEUTRALIZING ANTIBODY; NONSTRUCTURAL PROTEIN 3; PROTEIN VP2; PROTEIN VP7; VIRUS ANTIGEN; VIRUS VECTOR; CAPSID PROTEIN; CORE PROTEIN; LIVE VACCINE; NS3 PROTEIN, AFRICAN HORSE SICKNESS VIRUS; RECOMBINANT VACCINE; VIRUS ANTIBODY; VIRUS PROTEIN; VIRUS VACCINE; VP2 PROTEIN, AFRICAN HORSE SICKNESS VIRUS; VP7 MAJOR CORE ANTIGEN, AFRICAN HORSESICKNESS VIRUS;

AFRICAN HORSE SICKNESS VIRUS; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HORSE; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION PREVENTION; MOLECULAR CLONING; NONHUMAN; PILOT STUDY; RNA VIRUS INFECTION; VACCINATION; VIRUS RECOMBINANT; VIRUS STRAIN; WESTERN BLOTTING; ANIMAL; CHEMISTRY; IMMUNOLOGY; SERODIAGNOSIS;

AFRICAN HORSE SICKNESS VIRUS 4; AFRICAN HORSESICKNESS VIRUS; EQUIDAE;

AFRICAN HORSE SICKNESS VIRUS; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CAPSID PROTEINS; GENE EXPRESSION REGULATION; HORSES; NEUTRALIZATION TESTS; VACCINATION; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRAL CORE PROTEINS; VIRAL NONSTRUCTURAL PROTEINS; VIRAL VACCINES;

EID: 67650178090     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005997     Document Type: Article

References (59)

1. Mellor PS, Hamblin C (2004) African horse sickness. Vet Res 35: 445-466.
2. Meiswinkel R, Paweska JT (2003) Evidence for a new field Culicoides vector of African horse sickness in South Africa. Prev Vet Med 60: 243-253.
3. Mellor PS (1994) Epizootiology and vectors of African horse sickness virus. Comp Immunol Microbiol Infect Dis 17: 287-296.
4. Mellor PS, Boned J, Hamblin C, Graham S (1990) Isolations of African horse sickness virus from vector insects made during the 1988 epizootic in Spain. Epidemiol Infect 105: 447-454.
5. Mellor P, Capela R, Hamblin C, Hooghuis H, Mertens P, et al. (1994) African Horse Sickness in Europe: Epidemiology. In: Nakajima H, Plowright W, eds. Tokyo, 8-11 June 1994. R&W Publications (Newmarket) Ltd. pp 61-64.
6. Howell PG (1962) The isolation and identification of further antigenic types of African Horsesickness virus. Onderstepoort Journal of Veterinary Research 29: 139-149.
7. Roy P, Mertens PP, Casal I (1994) African horse sickness virus structure. Comp Immunol Microbiol Infect Dis 17: 243-273.
8. Burrage TG, Trevejo R, Stone-Marschat M, Laegreid WW (1993) Neutralizing epitopes of African horsesickness virus serotype 4 are located on VP2. Virology 196: 799-803.
9. Ranz AI, Miguet JG, Anaya C, Venteo A, Cortes E, et al. (1992) Diagnostic methods for African horsesickness virus using monoclonal antibodies to structural and non-structural proteins. Vet Microbiol 33: 143-153.
10. Mellor PS, Boorman J (1995) The transmission and geographical spread of African horse sickness and bluetongue viruses. Ann Trop Med Parasitol 89: 1-15.
11. Lubroth J (1988) African horse sickness and the epizootic in Spain 1987. Equine Practice 10: 26-33.
12. Rodriguez M, Hooghuis H, Castano M (1992) African horse sickness in Spain. Vet Microbiol 33: 129-142.
13. Sanchez-Vizcaino JM (2004) Control and eradication of African horse sickness with vaccine. Dev Biol (Basel) 119: 255-258.
14. Van Dijk AA (1999) African Horse Sickness Vaccine Development. In: Wernery U, Wade J, Mumford J, Kaaden O, eds. R&W Publications (Newmarket) Ltd.
15. OIE (2005) Terrestrial Animal Health Code. OIE, http://www.oie.int/eng/ Normes/mcode/en_chapitre_2.5.14.htm#rubrique_peste_equine.
16. House JA (1998) Future international management of African horse sickness vaccines. Arch Virol Suppl 14: 297-304.
17. Veronesi E, Hamblin C, Mellor PS (2005) Live attenuated bluetongue vaccine viruses in Dorset Poll sheep, before and after passage in vector midges (Diptera: Ceratopogonidae). Vaccine 23: 5509-5516.
18. House JA, Lombard M, Dubourget P, House C, Mebus CA (1994) Further studies on the efficacy of an inactivated African horse sickness serotype 4 vaccine. Vaccine 12: 142-144.
19. House JA, Lombard M, House C, Dubourget P, Mebus CA Efficacy of an inactivated vaccine for African Horse Sickness virus serotype 4; 1992; Paris, France. 1991 (June 17-21) CRC Press, Inc, pp. 891-895.
20. Du Plessis DH, Van Wyngaardt W, Gerdes GH, Opperman E (1991) Laboratory confirmation of African horsesickness in the western Cape: application of a F(ab')2-based indirect ELISA. Onderstepoort J Vet Res 58: 1-3.
21. Roy P, Bishop DH, Howard S, Aitchison H, Erasmus B (1996) Recombinant baculovirus-synthesized African horsesickness virus (AHSV) outer-capsid protein VP2 provides protection against virulent AHSV challenge. J Gen Virol 77(Pt 9): 2053-2057.
22. Kundig TM, Kalberer CP, Hengartner H, Zinkernagel RM (1993) Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccination. Vaccine 11: 1154-1158.
23. Rocha CD, Caetano BC, Machado AV, Bruna-Romero O (2004) Recombinant viruses as tools to induce protective cellular immunity against infectious diseases. Int Microbiol 7: 83-94.
24. Hanke T, Blanchard TJ, Schneider J, Hannan CM, Becker M, et al. (1998) Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine 16: 439-445.
25. Maclachlan NJ, Balasuriya UB, Davis NL, Collier M, Johnston RE, et al. (2007) Experiences with new generation vaccines against equine viral arteritis, West Nile disease and African horse sickness. Vaccine.
26. Drexler I, Staib C, Sutter G (2004) Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential? Curr Opin Biotechnol 15: 506-512.
27. Brochier B, Boulanger D, Costy F, Pastoret PP (1994) Towards rabies elimination in Belgium by fox vaccination using a vaccinia-rabies glycoprotein recombinant virus. Vaccine 12: 1368-1371.
28. Stone-Marschat MA, Moss SR, Burrage TG, Barber ML, Roy P, et al. (1996) Immunization with VP2 is sufficient for protection against lethal challenge with African horsesickness virus Type 4. Virology 220: 219-222.
29. Sutter G, Moss B (1992) Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci U S A 89: 10847-10851.
30. Meyer H, Sutter G, Mayr A (1991) Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol 72(Pt 5): 1031-1038.
31. Breathnach CC, Soboll G, Suresh M, Lunn DP (2005) Equine herpesvirus-1 infection induces IFN-gamma production by equine T lymphocyte subsets. Vet Immunol Immunopathol 103: 207-215.
32. Breathnach CC, Rudersdorf R, Lunn DP (2004) Use of recombinant modified vaccinia Ankara viral vectors for equine influenza vaccination. Vet Immunol Immunopathol 98: 127-136.
33. Wade-Evans AM, Pullen L, Hamblin C, O'Hara R, Burroughs JN, et al. (1997) African horsesickness virus VP7 sub-unit vaccine protects mice against a lethal, heterologous serotype challenge. J Gen Virol 78(Pt 7): 1611-1616.
34. Bougrine SI, Fihri OF, Fehri MM (1998) Western immunoblotting as a method for the detection of African horse sickness virus protein-specific antibodies: differentiation between infected and vaccinated horses. Arch Virol Suppl 14: 329-336.
35. Laviada MD, Roy P, Sanchez-Vizcaino JM, Casal JI (1995) The use of African horse sickness virus NS3 protein, expressed in bacteria, as a marker to differentiate infected from vaccinated horses. Virus Res 38: 205-218.
36. Andrew M, Whiteley P, Janardhana V, Lobato Z, Gould A, et al. (1995) Antigen specificity of the ovine cytotoxic T lymphocyte response to bluetongue virus. Vet Immunol Immunopathol 47: 311-322.
37. Janardhana V, Andrew ME, Lobato ZI, Coupar BE (1999) The ovine cytotoxic T lymphocyte responses to bluetongue virus. Res Vet Sci 67: 213-221.
38. Gubbins S, Carpenter S, Baylis M, Wood JL, Mellor PS (2008) Assessing the risk of bluetongue to UK livestock: uncertainty and sensitivity analyses of a temperature-dependent model for the basic reproduction number. J R Soc Interface 5: 363-371.
39. Purse BV, Mellor PS, Rogers DJ, Samuel AR, Mertens PP, et al. (2005) Climate change and the recent emergence of bluetongue in Europe. Nat Rev Microbiol 3: 171-181.
40. Wittmann EJ, Baylis M (2000) Climate change: effects on culicoides-transmitted viruses and implications for the UK. Vet J 160: 107-117.
41. Minke JM, Fischer L, Baudu P, Guigal PM, Sindle T, et al. (2006) Use of DNA and recombinant canarypox viral (ALVAC) vectors for equine herpes virus vaccination. Vet Immunol Immunopathol 111: 47-57.
42. Boone JD, Balasuriya UB, Karaca K, Audonnet JC, Yao J, et al. (2007) Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep. Vaccine 25: 672-678.
43. Minke JM, Toulemonde CE, Coupier H, Guigal PM, Dinic S, et al. (2007) Efficacy of a canarypox-vectored recombinant vaccine expressing the hemagglutinin gene of equine influenza H3N8 virus in the protection of ponies from viral challenge. Am J Vet Res 68: 213-219.
44. Poulet H, Minke J, Pardo MC, Juillard V, Nordgren B, et al. (2006) Development and registration of recombinant veterinary vaccines The example of the canarypox vector platform. Vaccine.
45. Breathnach CC, Clark HJ, Clark RC, Olsen CW, Townsend HG, et al. (2006) Immunization with recombinant modified vaccinia Ankara (rMVA) constructs encoding the HA or NP gene protects ponies from equine influenza virus challenge. Vaccine 24: 1180-1190.
46. Zhang X, Cassis-Ghavami F, Eller M, Currier J, Slike BM, et al. (2007) Direct comparison of antigen production and induction of apoptosis by canarypox virus- and modified vaccinia virus ankara-human immunodeficiency virus vaccine vectors. J Virol 81: 7022-7033.
47. Guirakhoo F, Catalan JA, Monath TP (1995) Adaptation of bluetongue virus in mosquito cells results in overexpression of NS3 proteins and release of virus particles. Arch Virol 140: 967-974.
48. Mertens PP, Brown F, Sangar DV (1984) Assignment of the genome segments of bluetongue virus type 1 to the proteins which they encode. Virology 135: 207-217.
49. Rooney JF, Wohlenberg C, Cremer KJ, Moss B, Notkins AL (1988) Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination. J Virol 62: 1530-1534.
50. Sharpe S, Polyanskaya N, Dennis M, Sutter G, Hanke T, et al. (2001) Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity. J Gen Virol 82: 2215-2223.
51. Abaitua F, Rodriguez JR, Garzon A, Rodriguez D, Esteban M (2006) Improving recombinant MVA immune responses: Potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma. Virus Res 116: 11-20.
52. McConkey SJ, Reece WH, Moorthy VS, Webster D, Dunachie S, et al. (2003) Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 9: 729-735.
53. Mertens P, Attoui H (2007) Isolates of African horse sickness virus (AHSV) in the dsRNA virus collection at IAH Pirbright. Institute for Animal Health, Pirbright. http://www.iah.bbsrc.ac.uk/ dsRNA_virus∥oteins/ReoID/AHSV-isolates. htm.
54. Maan S, Rao S, Maan NS, Anthony SJ, Attoui H, et al. (2007) Rapid cDNA synthesis and sequencing techniques for the genetic study of bluetongue and other dsRNA viruses. J Virol Methods 143: 132-139.
55. Chakrabarti S, Brechling K, Moss B (1985) Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques. Mol Cell Biol 5: 3403-3409.
56. Martinez-Torrecuadrada JL, Diaz-Laviada M, Roy P, Sanchez C, Vela C, et al. (1996) Full protection against African horsesickness (AHS) in horses induced by baculovirus-derived AHS virus serotype 4 VP2, VP5 and VP7. J Gen Virol 77(Pt 6): 1211-1221.
57. Martinez-Torrecuadrada JL, Diaz-Laviada M, Roy P, Sanchez C, Vela C, et al. (1997) Serologic markers in early stages of African horse sickness virus infection. J Clin Microbiol 35: 531-535.
58. Karber G (1931) Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Naunyn-Schmiedebergs Archiv fur experimentale Pathologie and Pharmacologie. pp 480-483.
59. Maree S, Paweska JT (2005) Preparation of recombinant African horse sickness virus VP7 antigen via a simple method and validation of a VP7-based indirect ELISA for the detection of group-specific IgG antibodies in horse sera. J Virol Methods 125: 55-65.